Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Michel Bazinet, Andrew Vaillant, Hrvoje Mijočević(Technical University of Munich), Adalbert Krawczyk(University of Duisburg-Essen), Valentin Cebotarescu(Nicolae Testemițanu State University of Medicine and Pharmacy), Pavlina Jimbei, Hadi Karimzadeh(Technical University of Munich), Victor Pântea(Université Claude Bernard Lyon 1), Michael Roggendorf(Technical University of Munich), Emmanuel Gordien(Inserm), Jeffrey H. Albrecht(University of Minnesota), Lilia Cojuhari(Nicolae Testemițanu State University of Medicine and Pharmacy), Peter Schmid(Queen Mary University of London), Frédéric Le Gal(Sorbonne Université)
Cited by 249
Related Papers
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RT-PCR for follow-up
|Hepatology|2006|238
Molecular Phylogenetic Analyses Indicate a Wide and Ancient Radiation of African Hepatitis Delta Virus, Suggesting a <i>Deltavirus</i> Genus of at Least Seven Major Clades
|Journal of Virology|2004|221
Eighth Major Clade for Hepatitis Delta Virus
|Emerging infectious diseases|2006|206
Inhibition of Hepatitis B Virus Replication by the Interferon-Inducible MxA Protein
|Journal of Virology|2001|185
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
|Journal of Viral Hepatitis|2011|178